Streetbeat News

Revenues

BMY

MRK

The FDA approved Merck & Co Inc's Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension (PAH), marking a significant milestone from its $11 billion acquisition of Acceleron Pharma Inc in 2021. Winrevair, priced at $14,000 per vial, is expected to become a standard of care for PAH, with projected peak sales of $5 billion by 2030. The approval is based on the Phase 3 STELLAR trial results, showing significant improvements in exercise capacity and reduction in clinical worsening events. Merck estimates Winrevair's availability in select U.S. specialty pharmacies by the end of April. The drug is also subject to a licensing agreement with Bristol Myers Squibb & Co.

Portfolio Pulse from Vandana Singh

March 27, 2024 | 1:20 pm

CCL

CUK

Carnival Corporation announced that due to an event in Baltimore and a temporary change in homeport, their guidance for the full year 2024 does not include an estimated impact of up to $10 million on both adjusted EBITDA and adjusted net income.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:19 pm

CUK

Carnival Corporation reported Q1 sales of $5.406 billion, missing the analyst consensus estimate of $5.473 billion by 1.22%. This represents a 21.98% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:16 pm

OPTX

Syntec Optics has received a $2.8 million order for opto-mechanical sub-systems used in night vision goggles. This order could indicate a significant boost in the company's operations and financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:14 pm

CPRX

Catalyst Pharmaceuticals (NASDAQ:CPRX) has received diverse analyst ratings over the past quarter, with a shift towards more bullish sentiments in recent months. The average 12-month price target for CPRX has risen to $29.29, indicating a positive outlook from financial experts. Analysts from firms like Oppenheimer, Cantor Fitzgerald, Citigroup, B of A Securities, and HC Wainwright & Co. have maintained or announced buy ratings, with price targets ranging from $23.00 to $34.00. Catalyst Pharmaceuticals, a biopharmaceutical company, has shown impressive financial performance with significant revenue growth, high net margin, and strong ROE and ROA, positioning it favorably in the market.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

SQ

Recent evaluations by 17 analysts on Block (NYSE:SQ) show diverse outlooks, ranging from bullish to bearish. The average 12-month price target for SQ is now $88.47, up 12.99% from the previous $78.30, with high estimates reaching $100.00. Analyst actions include upgrades and maintenance of ratings, reflecting optimism in Block's performance and market position. Despite a market cap below industry averages, Block's revenue growth stands out at 24.13%, though it faces challenges in profitability and returns metrics.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

CUBE

Four financial analysts have recently shared mixed evaluations of CubeSmart (NYSE:CUBE), with ratings ranging from bullish to bearish. The average 12-month price target for CUBE has been raised to $46.5, indicating a 14.81% increase from the previous target. Analysts from Barclays, Evercore ISI Group, Deutsche Bank, and Jefferies have adjusted their ratings and price targets, reflecting changing market conditions and CubeSmart's performance. CubeSmart, a real estate investment trust focusing on self-storage facilities, has shown solid revenue growth and impressive profitability metrics, despite a market capitalization below industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

REXR

Analysts have diverse views on Rexford Industrial Realty (REXR), with recent evaluations ranging from bullish to bearish. The average 12-month price target is $54.5, down from $57.00. Analyst actions include adjustments to ratings and price targets by Barclays, Truist Securities, JP Morgan, and Baird. Rexford, a REIT focusing on industrial properties in Southern California, has shown strong financial performance with notable revenue growth, high net margin, and efficient asset and equity management.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

SNX

TD Synnex (NYSE:SNX) has received consistent 'Indifferent' ratings from 4 analysts over the past three months, with a positive shift in the 12-month price target to $113.5, up 5.58% from $107.50. Analysts from Barclays, CFRA, RBC Capital, and JP Morgan have raised their price targets, reflecting a cautiously optimistic outlook despite TD Synnex's recent financial challenges, including a -11.33% revenue decline and below-industry-standard profitability metrics.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

LUXH

LuxUrban reported its preliminary Q4 2023 revenue to be $28.2 million, which is below the estimated $34.199 million.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:51 pm